Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Astrazeneca Pharma India Ltd has experienced a nuanced shift in its technical momentum, with recent data revealing a transition from a sideways trend to a mildly bearish stance. Despite a modest day gain of 0.61%, the stock’s technical indicators present a complex picture, reflecting both bullish and bearish signals across weekly and monthly timeframes.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

AstraZeneca Pharma India Ltd. reported a challenging quarter for Q4 FY26 (January-March 2026), with net profit declining to ₹44.88 crores, down 22.96% quarter-on-quarter (QoQ) from ₹58.25 crores in Q3 FY26, despite posting robust revenue growth of 20.42% year-on-year (YoY). The stock reacted sharply to the mixed results, declining 5.17% to close at ₹8,520.00 on May 27, 2026, as investors grappled with deteriorating margins and profitability concerns despite the company's strong topline momentum.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a 2.19% gain on 20 May 2026, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This nuanced technical landscape warrants a detailed analysis for investors seeking clarity on the stock’s near-term trajectory.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 May 2026, providing investors with an up-to-date view of its performance and outlook.

Astrazeneca Pharma India Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical indicators suggest a cautiously evolving outlook for this small-cap pharmaceutical player.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO. This rating was last updated on 02 Jan 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 06 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a bearish to a mildly bearish trend as of early 2026. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s mixed technical signals across key indicators such as MACD, RSI, Bollinger Bands, and moving averages suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Despite some bullish signals on longer-term indicators, the overall technical landscape suggests caution for investors as the stock contends with downward pressure amid mixed momentum indicators and a recent downgrade in its Mojo Grade to Sell.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 April 2026, providing investors with the latest insights into its performance and outlook.

Astrazeneca Pharma India Ltd has experienced a notable shift in price momentum, reflected in a 5.21% gain on 15 Apr 2026, as technical indicators reveal a complex picture of mildly bearish to bullish signals across weekly and monthly timeframes. Despite a recent downgrade from Hold to Sell by MarketsMOJO, the stock’s long-term returns remain robust, outperforming the Sensex over multiple periods.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO. This rating was last updated on 02 Jan 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 14 April 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 03 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Astrazeneca Pharma India Ltd experienced a significant intraday decline on 27 Mar 2026, touching a low of Rs 7,825, down 7.02% from the previous close. The stock underperformed its sector and broader market indices amid widespread selling pressure and bearish technical signals.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO. This rating was last updated on 02 Jan 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 23 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating moving averages and mixed signals from momentum oscillators, suggests caution for investors amid a challenging market backdrop.